Articles tagged with Drug Discovery
Researchers at the University of Zurich have developed a new method for alleviating chronic itch by targeting specific neurons in the spine that prevent itch signals from being relayed to the brain. The experimental drug has been shown to be effective in mice and dogs, with significant reductions in scratching and improved skin healing.
Scripps Research scientists have developed a powerful new strategy for synthesizing molecular skeletons of chemicals used in drugs and other important products. The method combines two chemical reactions, C-C cross coupling and cycloaddition, providing unprecedented flexibility and control over chemical synthesis.
The Harrington Discovery Institute has announced three new scholars in collaboration with FFB and ADDF, selected through a competitive review process for their research on therapies for retinal degenerative diseases and Alzheimer's disease. The institute provides financial support and drug development assistance to accelerate these pro...
A new compound with potential to treat visceral leishmaniasis has been discovered through collaboration between the University of Dundee, GSK and Wellcome. The compound works by inhibiting an enzyme called CRK12, offering a novel approach to tackling the disease.
This special issue showcases recent advances in high-throughput flow cytometry for drug discovery, including novel applications and expert insights. Examples include HTFC for single-cell analysis, biologic drugs, and CAR-T therapy.
Researchers at the University of Pennsylvania and Syracuse University have developed a compound that effectively controls hyperglycemia in animal trials without causing nausea and vomiting. The modified compound is less absorbed into brain regions that trigger these side effects, leading to vastly improved tolerance.
Researchers at Cardiff University have developed a potential new treatment for schistosomiasis and fascioliasis, two devastating tropical diseases. The goji berry-derived drug compound shows promise in combating the parasites that cause these conditions.
Scientists have identified two small-molecule compounds that specifically target the STING protein, which plays a key role in triggering an immune response. These compounds effectively blocked STING-mediated cellular activation and demonstrated therapeutic potential in mouse models of autoinflammatory disease.
Researchers at University of Otago have discovered a novel property of Bedaquiline, a new anti-tuberculosis drug that could help develop more effective treatments for tuberculosis. The study's findings suggest that the drug works by disrupting energy generation in Mycobacterium tuberculosis cells, offering potential for designing more ...
Insilico Medicine introduces a novel deep neural network architecture called Reinforced Adversarial Neural Computer (RANC) for de novo molecular design. RANC outperforms other methods in generating unique structures and passing medical chemistry filters.
AcuraStem has been awarded a $3.7 million SBIR grant to continue research on a small molecule therapeutic for ALS, utilizing induced motor neuron cellular models and precision platform iNeuroRx°. The grant supports the development of AS2015, targeting expansion repeats in the C9ORF72 gene.
A new study by Scripps Research reveals that bacteria-derived molecules called thiocarboxylic acids have potential as warheads and could be used to create more effective drugs. The discovery was made after researchers found that these natural products can bind to biological targets better than lab-made molecules.
A recent international agreement emphasizes the need for human-relevant research in drug discovery, citing a significant decline in successful new drug approvals. The agreement proposes standardized data sharing, consistent ontologies, and prioritization of human-based methods to revitalize the drug development process.
Researchers discovered a chemical compound that lowers sugar levels as effectively as metformin but with a 30-times lower dose, providing an alternative treatment option for patients unresponsive to the current medication. The study published in PLOS One could lead to the development of a new and effective drug to fight diabetes.
Researchers at UBC's Okanagan campus found that men who have used psychedelic drugs are less likely to engage in partner violence. The study suggests that psychedelics may help improve emotion regulation and reduce violent tendencies.
Clinical Trials in a Dish (CTiD) offers a novel strategy to test drugs on patient cells before moving into actual clinical trials. CTiD studies have opened up new avenues for screening cell-based safety and toxicity at the population level, enabling efficient testing with reduced costs.
Researchers have found a link between bacteria metabolism and cell-to-cell communication, which could lead to the development of new drugs that block toxic molecules or prevent biofilm formation. By disrupting quorum sensing and biofilm forming in bacteria, these drugs may prevent infections such as urinary tract infections.
The study reveals unexpected molecular behavior in ultra-nanoscale channels, where neutral molecules behave as though carrying a charge. The team developed an algorithm for selecting optimal nanochannel size for each drug, but found that current theories were unable to explain the observed effects.
Researchers at Duke University have developed a technique to capture RNA molecules in precise images, revealing new opportunities for drug discovery. The method identifies potential anti-HIV compounds from millions of possibilities, showcasing its accuracy and potential to treat various ailments.
Eight out of ten transformative medicines in the US between 1985 and 2009 originated from fundamental discoveries, with an average time to approval of 30 years. Curiosity-driven science is essential for discovering new medicines.
Researchers have discovered an alternative strategy to combat antimicrobial resistance by repositioning colloidal bismuth subcitrate, which effectively paralyzes multi-resistant superbugs and suppresses the development of antibiotic resistance. The findings offer a promising new approach to treat deadly infections caused by CRE and CRKP.
Researchers at Nagoya University have successfully determined the crystal structure of the gastric proton pump, a key enzyme in stomach acid secretion. The study sheds light on how the pump expels hydrogen ions into the stomach despite its acidic environment.
Biogerontology Research Foundation's Chief Science Officer, Professor Alexander Zhavoronkov, will share his projections on how AI is set to revolutionize biopharma for aging and biomarker discovery. He will reveal the latest progress in AI and drug discovery at Pioneers18 in Vienna.
Researchers at Trinity College Dublin have discovered a potential 'off-switch' for inflammation by identifying the molecule itaconate, which can block production of inflammatory factors and protect against lethal inflammation. This breakthrough could lead to new anti-inflammatory medicines for diseases such as arthritis and heart disease.
A study discovered that an experimental drug connected to fat regulation prevents the formation of kidney stones in mice. The researchers found that the β3-agonist reduced inflammation in kidneys by consuming free fatty acids, potentially preventing both obesity and kidney stones. Further studies are needed to confirm these findings.
LSU researchers developed a computer-assisted drug repositioning process to identify existing drugs for rare diseases. They matched protein structures and functions with existing drug interactions to help patients receive effective treatment.
Researchers at TSRI have developed a new desulfonylative cross-coupling reaction that simplifies the synthesis of drug-like molecules, including alkyl-fluorinated compounds. This method paves the way for creating new types of compounds and facilitating the synthesis of pharmaceuticals.
University of Alberta researchers have found the Ebola polymerase enzyme, which may lead to more effective research and better treatments for the often fatal infection. The discovery allows for the study of Ebola inhibitors in any lab environment, accelerating the search for antiviral medicines.
Researchers at Australian National University have identified molecular similarities across six pharmaceutical drugs to reduce unwanted side effects. The study, published in Proceedings of the National Academy of Sciences, aims to inform future scientists on how to design more specific drugs with fewer side effects.
Researchers propose roadmap for making humans resistant to radiation and stress damage, with a focus on radioresistance. The strategies aim to maximize productive life years in space, addressing challenges like high-LET radiation.
McMaster University engineers have developed a printed paper-based device that speeds up and improves the accuracy of drug screening. The technology uses a printable hydrogel to filter out inaccurate results, reducing the time and cost associated with drug discovery.
Researchers at U of T have designed a new antimicrobial material to minimize recurrent caries under fillings, affecting 100 million patients annually. The novel material packs 50 times more bacteria-fighting drugs than traditional options, offering a potential solution to this common dental problem.
Researchers at University of Toronto have developed technology for creating durable disease-fighting molecules that can last longer in the body, reducing frequent drug injections. Mirror-image versions of existing drugs, such as GLP1 and PTH, have been created using computational approach, showing longer-lasting effects on cells.
Researchers at University of Bristol have successfully trapped objects larger than the wavelength of sound in an acoustic tractor beam, paving the way for levitation of humans. The discovery uses rapidly fluctuating acoustic vortices, which are stabilised by controlling the rate of rotation.
Researchers at the University of Kansas have developed a method to screen millions of human antibodies for rapid therapeutic discovery, overcoming limitations of single-cell cloning. The breakthrough technology identifies highly potent antibodies and provides insights into human immune responses to vaccines and infections.
A novel deep-learning based hematological human aging clock predicts the biological age of individual patients with high accuracy. The model outperforms chronological age in predicting all-cause mortality, highlighting population-specific patterns of aging.
A new machine-learning model can accurately predict protein-drug interactions based on a few reference experiments or simulations, accelerating the screening of candidate molecules thousands of times over. The algorithm can also tackle materials-science problems, revolutionizing materials and chemical modeling.
Researchers at The University of Manchester have discovered that uranium can perform reactions previously thought impossible, opening the door to new ways of producing materials and chemicals. This breakthrough could lead to the creation of truly biodegradable hard plastic and new medicines.
Researchers have validated five new genes responsible for Amyotrophic Lateral Sclerosis (ALS), a fatal neurological disorder. The study uses AI-powered technology to accelerate the discovery of new treatments by identifying key proteins linked to the disease.
Aric Rogers' research discovered that NMD plays a critical role in extending lifespan under dietary restriction conditions. The grant will help expedite the development of 'DR mimetics,' drugs that mimic the effects of DR on longevity, potentially leading to new therapies.
The new Connectivity Map includes over 1.3 million gene expression profiles from multiple cell lines treated with chemical or genetic perturbations, enabling the study of small molecule and gene function. This expanded resource accelerates drug discovery efforts by predicting how small molecules work and discovering compounds with spec...
A study published in the Journal of Consumer Psychology found that consumers are more likely to engage in dishonest behavior, such as shoplifting or piracy, if they perceive a company as harming the environment or people. This effect occurs even when consumers have not personally had a bad experience with the company.
A UCL-led study found that inhibiting RNA polymerase III, a common enzyme in all animals, extends the lifespans of yeast cells and animals by an average of 10%. This discovery may lead to targeted anti-aging therapies, similar to the effects of rapamycin.
Scientists at the University of Edinburgh have identified two molecules, SMAD2 and SMAD3, that enhance cellular reprogramming efficiency. This breakthrough could accelerate production of induced pluripotent stem cells for studying diseases like multiple sclerosis and Parkinson's disease.
Researchers from Insilico Medicine and BitFury Group present a blockchain-based life data interchange system to decentralize and accelerate biomedical research. The system utilizes deep learning technologies to analyze human life data, reducing biases and democratizing healthcare access.
A new technique, ligand-accelerated non-directed C-H functionalization, enables the late-stage modification of complex drug molecules to improve therapeutic properties. Researchers used a special ligand molecule called 2-pyridone to enhance palladium's reactivity with targeted C-H bonds.
Researchers have discovered that glatiramer acetate, a widely used multiple sclerosis treatment, can also effectively kill certain multi-resistant bacteria. This breakthrough opens up new possibilities for treating cystic fibrosis patients and may even provide insight into the underlying causes of multiple sclerosis.
A new study by Sanford Burnham Prebys Medical Discovery Institute found that chloroquine, an anti-malarial drug, reduces the transmission of Zika virus from mother to fetus. The research suggests that chloroquine may be effective in treating and preventing Zika infections.
Anita Mattson's research focuses on naturally occurring molecules known as dimeric chromanones, which have high biological activity and may become powerful dual-action treatments for drug-resistant cancers. Her goal is to develop a new class of catalysts using silanediols to control the synthesis of these compounds.
A new model proposes returning control over human life data to patients, accelerating biomedical research through a secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies. This approach can resolve challenges faced by regulators and improve patient satisfaction.
A new technique using blue LED lights and catalysts reduces the time to create radioactive molecules from months to hours, accelerating the arrival of new drugs to the marketplace. This innovation has the potential to bring medicines to patients much faster than before.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
A new combination therapy using registered drugs albendazole and antibiotics has dramatically shortened treatment time for lymphatic filariasis and onchocerciasis, reducing it from weeks to just seven days. This breakthrough could accelerate elimination of these debilitating diseases, prioritized by the UN's Sustainable Development Goals.
Researchers at Rutgers University have identified a protein complex called TldD that activates the antibiotic microcin B17 by removing its protective coating. This discovery could lead to the development of new antibacterial agents and drugs to combat toxins.
Insilico Medicine showcases its use of artificial intelligence to identify disease targets, generate molecular structures, and track interventions for metabesity. The company aims to prevent metabolic-rooted disorders such as diabetes and dementia.
A new AI model called druGAN enables the generation of novel molecules with desired properties, surpassing previous GAN-based approaches. The model uses reinforcement learning to generate effective molecular graphs, paving the way for improved pharmaceuticals.
Researchers demonstrate an engineering approach to combine four drugs and control parasitic worms, a major breakthrough in treating nematode infections. The technique, developed by Chih-Ming Ho, uses a feedback system to quickly identify potent drug combinations that are effective on a small-animal model organism.
Researchers studied HIV drug combinations to understand why some drugs act synergistically while others do not. They found that virus protein mutations and host cell receptor density affect synergy, highlighting the need for personalized treatment approaches.
Scientists have developed a new sensor that can detect minute concentrations of methamphetamine and amphetamine in urine, allowing for real-time drug screening. The sensor uses a pumpkin-shaped molecule to bind with the drugs, triggering an electrical signal that appears on a smartphone screen.
The Children's Tumor Foundation and PLOS ONE are collaborating on a new funding program in neurofibromatosis (NF) research, integrating the Registered Reports model to enhance rigor, reproducibility, and transparency. The partnership aims to accelerate transparent science and eliminate publication bias.